Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 12:12 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 4,112 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Experimental 2 Clear all

Conditions: Alzheimer Disease, Mild Cognitive Impairment (MCI), Dementia
Interventions: 18F-MK6240, 18F-Florbetaben (FBB); Drug
Lead sponsor: Patrick Lao; Other
Eligibility: 50 Years and older
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2033
U.S. locations: 1
States / cities: New York, New York

Conditions: HIV Prevention, Transgender Women
Interventions: Alternative long-acting PrEP injection strategies, mHealth adherence app; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: T-cell Prolymphocytic Leukemia, Refractory T-Cell Prolymphocytic Leukemia
Interventions: Ruxolitinib, Cladribine, Venetoclax; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Healthy
Interventions: ADX48621, [18F]FPEB; Drug · Radiation
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Lymphoblastic Leukemia, Cancer Survivors, Aplastic Anemia, Myelodysplastic Syndromes, Myeloid Leukemia
Interventions: Nicotinamide Riboside, Placebo, Exercise Intervention; Dietary Supplement · Other
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 10 Years to 30 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 3
States / cities: Duarte, California • Philadelphia, Pennsylvania • Memphis, Tennessee

Conditions: Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis
Interventions: Investigational Liver Fat Quantification Software; Device
Lead sponsor: Philips Clinical & Medical Affairs Global; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 3
States / cities: Boston, Massachusetts • Boardman, Ohio

Conditions: Hernia, Diaphragmatic, Hypertension, Pulmonary, Hypoplasia, Pulmonary
Interventions: sildenafil, Placebo; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 10 Days to 42 Days
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 3
States / cities: Los Angeles, California • San Francisco, California • Chicago, Illinois

Conditions: Metastatic Non Small Cell Lung Cancer
Interventions: Pembrolizumab/Vibostolimab coformulation, Docetaxel, Placebo; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 10
States / cities: Los Angeles, California • Peoria, Illinois • Lexington, Kentucky + 7 more

Conditions: Primary Biliary Cholangitis, Compensated Cirrhosis, Hepatic Impairment
Interventions: Seladelpar; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 11
States / cities: Chandler, Arizona • Sacramento, California • Aurora, Colorado + 7 more

Conditions: Dry Eye Disease
Interventions: FID123300 ocular lubricant; Other
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 188 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 9
States / cities: Maitland, Florida • Orlando, Florida • Franklin Park, Illinois + 6 more

Conditions: Amputation, Upper Limb
Interventions: RESCU, Pattern Recognition; Device
Lead sponsor: Infinite Biomedical Technologies; Industry
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Silver Spring, Maryland

Conditions: Sleep Restriction
Interventions: Additional protein and multi-nutrient beverage, Placebo beverage; Other
Lead sponsor: United States Army Research Institute of Environmental Medicine; Federal
Eligibility: 18 Years to 45 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Natick, Massachusetts

Conditions: Overweight and Obesity, Body Weight Changes, Healthy Lifestyle, Exercise, Dietary Supplement
Interventions: Phaeosol group, Placebo group; Dietary Supplement
Lead sponsor: Microphyt; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: College Station, Texas

Conditions: Sickle Cell Disease
Interventions: Music therapy, Health education; Behavioral · Other
Lead sponsor: University of California, Irvine; Other
Eligibility: 14 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Cleveland, Ohio • Greenville, South Carolina

Conditions: GVHD, Hematologic Neoplasms
Interventions: Cyclophosphamide, abatacept, Methotrexate, Tacrolimus; Drug
Lead sponsor: Dimitrios Tzachanis, MD PhD; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Dental Pain
Interventions: Full Dose Strength, Quarter dose strength, Half dose strength, Acetaminophen standard dose, Ibuprofen low dose, Ibuprofen high dose, Placebo; Drug
Lead sponsor: AFT Pharmaceuticals, Ltd.; Industry
Eligibility: 16 Years to 40 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Lung Cancer, Non-small Cell, Lung Cancer Metastatic, Solid Tumor, Adult, Advanced Cancer, Lung Cancer (NSCLC)
Interventions: KB707, Pembrolizumab (KEYTRUDA®), Chemotherapy, Docetaxel; Biological · Drug
Lead sponsor: Krystal Biotech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 14
States / cities: Dothan, Alabama • Scottsdale, Arizona • Beverly Hills, California + 11 more

Conditions: Motivation, Memory, Self-regulation
Interventions: Ventral tegmental area of dopaminergic midbrain (VTA) fMRI neurofeedback; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 45 Years
Enrollment: 190 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Disuse Atrophy
Interventions: Profile Perform, Lower Limb Suspension; Dietary Supplement · Other
Lead sponsor: South Dakota State University; Other
Eligibility: 18 Years to 25 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Brookings, South Dakota

Conditions: Diabetic Foot Ulcer, Amniotic Membrane Placental Allograft, Biologic
Interventions: Standard of Care, BIOxHEAL (human amniotic membrane allograft); Other · Biological
Lead sponsor: Applied Biologics, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 253 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Boardman, Ohio

Conditions: Influenza, Human
Interventions: ARCT-2304, Control vaccine younger adults, Control vaccine older adults, Placebo Vaccine; Biological · Other
Lead sponsor: Arcturus Therapeutics, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 212 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 4
States / cities: La Mesa, California • San Bernardino, California • Longmont, Colorado + 1 more

Conditions: Pain
Interventions: Acetaminophen, placebo; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 21 Years to 45 Years · Female only
Enrollment: 99 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Pulmonary Arterial Hypertension
Interventions: PF-07868489, Placebo for PF-07868489; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 97 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 16
States / cities: Anaheim, California • Costa Mesa, California • Orange, California + 5 more

Conditions: Healthy Adult Male and Female Volunteers
Interventions: Low-frequency whole-body vibration mat; Device
Lead sponsor: Florida International University; Other
Eligibility: 18 Years to 45 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Miami, Florida

Search by objective public record fields.

Alzheimer's Disease Research Center (ADRC) PET Component Study

Long-acting Biomedical HIV Prevention in Transgender Women

Phase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic Leukemia

PET Imaging Study to Evaluate the mGlu5r Occupancy Following ADX48621 (Dipraglurant) Administration

Exercise Training and NR Supplementation Trial to Improve Fitness in AYA HCT Survivors

Ultrasound-Based Liver Fat Quantification (LFQ) Pilot Study

Chronic Sildenafil for Severe Diaphragmatic Hernia

Pembrolizumab/Vibostolimab Coformulation (MK-7684A) or Pembrolizumab/Vibostolimab Coformulation Plus Docetaxel Versus Docetaxel for Metastatic Non Small Cell Lung Cancer (NSCLC) With Progressive Disease After Platinum Doublet Chemotherapy and Immunotherapy (MK-7684A-002, KEYVIBE-002)

An Open-Label Study Following Oral Dosing of Seladelpar to Participants With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)

Study of Safety and Performance of a Novel Ocular Lubricant in Subjects With Dry Eye Disease

RESCU System for Robust Upper Limb Prosthesis Control

Nutrition Intervention to Promote Immune Recovery From Sleep Restriction

Microalgae Extract Phaeosol Combined to Exercise in Healthy Overweight Women : Efficacy on Body Weight Management

MULTIsite Feasibility of MUSIc Therapy to Address Quality Of Life in Sickle Cell Disease

Comparing Cyclophosphamide and Abatacept With Standard of Care Treatment Following Stem Cell Transplantation

Maxi-Analgesic Phase 2 Study to Compare the Analgesic Effects in Different Dosing Groups to Treat Teeth Extraction Pain

A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs

MRI Neurofeedback and Brain Circuits Related to Motivation in Healthy Participants

The Efficacy of Protein Supplementation on Attenuating Muscle Atrophy Following Disuse in the Collegiate Population

a Prospective, Multicenter, Randomized Controlled Trial, With a Non-randomized Sentinel Cohort, Evaluating the Efficacy of Bioxheal, a Single-layer Placental-derived Biologic in Nonhealing Diabetic Foot Ulcers

Safety and Immunogenicity Study of Self-Amplifying RNA Pandemic Influenza Vaccine in Adults

A Randomized Controlled Trial of Oral Acetaminophen for Analgesic Control After Transvaginal Oocyte Retrieval

A Study to Learn About the Study Medicine Called PF-07868489 in Healthy Adult People and in People With Pulmonary Arterial Hypertension

Evaluating a Mat-Based Biometric Vibration System for Sleep and Daily Recovery